How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study

Shilpa Gupta, Yohann Loriot, Michiel S. Van der Heijden, Jens Bedke, Begoña P. Valderrama, Eiji Kikuchi, Aude Fléchon, Daniel Petrylak, Maria De Santis, Matthew D. Galsky, Jae Lyun Lee, Umang Swami, Srikala S. Sridhar, Ugo De Giorgi, Phoebe Wright, Vanessa Shih, Yi-Tsung Lu, Xuesong Guan, Ryan Dillon, Aditya Shetty, Blanca Homet Moreno, Jennifer L. Beaumont, Intan Purnajo, Shauna McManus, Thomas Powles

Open source

DOI: 10.1080/14796694.2026.2645984
Published: 2026-04-02
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2645984,
  title = {How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study},
  author = {Shilpa Gupta and Yohann Loriot and Michiel S. Van der Heijden and Jens Bedke and Begoña P. Valderrama and Eiji Kikuchi and Aude Fléchon and Daniel Petrylak and Maria De Santis and Matthew D. Galsky and Jae Lyun Lee and Umang Swami and Srikala S. Sridhar and Ugo De Giorgi and Phoebe Wright and Vanessa Shih and Yi-Tsung Lu and Xuesong Guan and Ryan Dillon and Aditya Shetty and Blanca Homet Moreno and Jennifer L. Beaumont and Intan Purnajo and Shauna McManus and Thomas Powles},
  year = {2026},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2026.2645984},
  url = {https://doi.org/10.1080/14796694.2026.2645984}
}

RIS

TY  - JOUR
TI  - How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study
AU  - Shilpa Gupta
AU  - Yohann Loriot
AU  - Michiel S. Van der Heijden
AU  - Jens Bedke
AU  - Begoña P. Valderrama
AU  - Eiji Kikuchi
AU  - Aude Fléchon
AU  - Daniel Petrylak
AU  - Maria De Santis
AU  - Matthew D. Galsky
AU  - Jae Lyun Lee
AU  - Umang Swami
AU  - Srikala S. Sridhar
AU  - Ugo De Giorgi
AU  - Phoebe Wright
AU  - Vanessa Shih
AU  - Yi-Tsung Lu
AU  - Xuesong Guan
AU  - Ryan Dillon
AU  - Aditya Shetty
AU  - Blanca Homet Moreno
AU  - Jennifer L. Beaumont
AU  - Intan Purnajo
AU  - Shauna McManus
AU  - Thomas Powles
PY  - 2026
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2645984
UR  - https://doi.org/10.1080/14796694.2026.2645984
ER  -

APA

Gupta, S., Loriot, Y., Heijden, M. S. V. D., Bedke, J., Valderrama, B. P., Kikuchi, E., Fléchon, A., Petrylak, D., Santis, M. D., Galsky, M. D., Lee, J. L., Swami, U., Sridhar, S. S., Giorgi, U. D., Wright, P., Shih, V., Lu, Y., Guan, X., Dillon, R., Shetty, A., Moreno, B. H., Beaumont, J. L., Purnajo, I., McManus, S., & Powles, T. (2026). How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study. Future Oncology. https://doi.org/10.1080/14796694.2026.2645984

Source records

crossref · retrieved 2026-09-26T03:28:31.519Z